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10−/− mice. The molecular mechanism of this beneficial effect possibly involves the downregulation of
Stat3 and noncanonical NF-฀b activation. Anti-CD4 treatment reduced Th1 and Th2 signature but did
not alleviate AIP. Additionally, in contrast to anti-CD20 or anti-CD4 treatments, blocking LT฀R signaling
disrupted tertiary lymphoid organs in all three models. We demonstrate that treatment with LT฀R-Ig
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ABSTRACT
Autoimmune pancreatitis (AIP) is a rare form of chronic pancreatitis, for which treatment options, especially the long-term
management, are limited. The only therapy that has been established and accepted so far is corticosteroids, but the relapse rate
is significant. In the current study, we discern the effector mechanisms of targeted LTbR pathway inhibition using LTbR-Ig.
Furthermore, the efficacy of LTbR-Ig therapy is compared with the depletion of immune cell subsets (CD4+ and CD20+), which are
suggested to play a pathological role in AIP development. Three well-established mouse models of AIP were used to examine
treatment efficacies and mechanisms. Tg(Ela1-Lta,b) mice represent a genetic model, in which AIP develops spontaneously. In
MRL/Mp and IL-102/2 mice, AIP is induced by repeated polyinosinic:polycytidylic acid injection. Mice with AIP were treated with
anti-CD20, anti-CD4 mAbs, or targeted LTbR-Ig. LTbR-Ig and anti-CD20 treatment led to significant improvement of AIP, including
a decrease in autoantibody production and pancreatic inflammation in Tg(Ela1-Lta,b) and IL-102/2 mice. The molecular mechanism
of this beneficial effect possibly involves the downregulation of Stat3 and noncanonical NF-kb activation. Anti-CD4 treatment
reduced Th1 and Th2 signature but did not alleviate AIP. Additionally, in contrast to anti-CD20 or anti-CD4 treatments, blocking LTbR
signaling disrupted tertiary lymphoid organs in all three models. We demonstrate that treatment with LTbR-Ig or anti-CD20 Ab
alleviated murine AIP. LTbR-Ig treatment for AIP was effective in both lymphotoxin-dependent and lymphotoxin-independent
AIP models, possibly because of its dual anti-inflammatory and antiautoimmune mechanisms. ImmunoHorizons, 2020, 4: 688–700.
INTRODUCTION
Autoimmunepancreatitis (AIP) is a rare disease, but its prevalence
is rising. This might be due to improved clinical assessment but
also due to an overall increase in autoimmune diseases in
industrialized countries. Consequently, the interest in treating
patients effectively with novel therapies will also increase in the
future. Thus, thorough understanding of the cellular and molecular
mechanisms driving AIP is urgently needed to develop novel
therapies supporting current standard of care. With improved
understanding of AIP and its distinct clinical profiles and
variable association with a systemic IgG4 disease process (1),
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AIP has been classified into type 1 and type 2 AIP: In type 1 AIP,
the pancreas is affected as part of a systemic IgG4-positive
disease and is characterized by lymphoplasmacytic infiltration
accompanied by high endothelial venules and germinal center
formation, hypergammaglobulinemia (IgG4), and vasculitis (2).
Type 2 AIP is a fibroinflammatory duct-centric type with
granulocyte epithelial lesions and pancreatic duct destruction
without IgG4-positive cells or systemic involvement. Between
the two entities, type 1AIP is themore common formworldwide.
The cause of AIP is not completely understood. As suggested
by its name, the immune system, both cellular and humoral compo-
nents, is involved in the pathophysiology of AIP. However, it is
still debated whether the immune system induces or only
maintains AIP (3). One mechanism that possibly contributes to
AIP development is a local inflammatory reaction. The release of
proinflammatory cytokines may attract self-reactive T cells to
initiate damage to local target tissues. In this context, autoimmu-
nity does not initiate disease but may contribute to its chronicity
(4). Based on the observation that lymphotoxin (LT) a and b
are involved in the local inflammatory reaction during AIP, a
transgenic mouse model with pancreas-specific LT expression
was generated (5). This transgenicmousemodel [Tg(Ela1-Lta,b)]
recapitulates several features of human AIP. Type 1 AIP in Tg
mice is characterized by 1) the development of Abs against
pancreatic self-antigens, 2) the presence of anti-nuclear Ab, 3)
the rise in total serum IgG, and4) extrapancreaticmanifestation,
mainly in the kidney in the form of IgG deposits in the glomeruli.
In Tg(ELa1-Lta,b) mice, the localized inflammation in the
pancreas developed into AIP and systemic autoimmune disease
between 9 and 12 mo of age, suggesting that local inflammatory
reactions are involved in AIP pathogenesis. The Tg(ELa1-Lta,b)
model is an aetiologically relevant preclinical animal model,
with spontaneous disease initiation; therefore, it is an ideal
model for studyingdisease pathogenesis and fordiscovering new
treatment strategies for AIP.
Currently, AIP patients are treatedwith corticosteroids,which
promptly reduce inflammation and lead to morphological and
clinical remission inmostcases.Despite thehigh initial response in
the case of type 1AIP, the disease ispredicted to relapse in 30–50%
of patients. On the contrary, in type 2 AIP, disease relapses are
rather uncommon (6). Although there is a general agreement that
steroids are the ideal initial treatment, there is no clear consensus
regarding the treatment of disease relapses (7). An additional high
dose of steroids is the most commonly used treatment for
managing disease relapse in type 1 AIP (7). In some instances of
refractory or recurrent AIP, a steroid-sparing maintenance with
immunomodulatory (IM) drugs is used. Experimental studies in
mice have indicated that T cells have amajor role in AIP induction
and that cyclosporine and rapamycin could be alternatives to
standard steroid treatment (8). Although approximately half of the
patients with recurrent AIP might benefit from IM treatment, a
significantgroup is resistant toIMsor intolerant tosteroids.Forsuch
patients, treatment directed against B cells (e.g., with the anti-CD20
[aCD20] Ab rituximab) was shown to be effective. A few single case
reports (9, 10) and a recent study at the Mayo Clinic (11) yielded
encouragingresults regarding theuseof rituximab in thesettingAIP.
Based on a limited follow-up, the risks of disease relapse and
treatment-relatedsideeffectswere low.Althoughtheseobservational
data showed a definite benefit of rituximab for treating IgG4-related
diseases, the molecular mechanisms of this therapy are still unclear.
Therefore, further studies to investigate the biological effects of
rituximab and refining new therapeutic strategies are needed.
In the Tg(Ela1-Lta,b) model, we have previously shown that in
contrast to corticosteroids, which only diminished inflammation,
inhibition of LTb receptor signaling (LTbR-Ig)was able to abrogate
autoimmunity. To explore the benefits of LTbR-Ig treatment, in this
study,weaimedat investigatingmechanismsbehindtheeffectiveness
of LTbR inhibition. Furthermore, we tested LTbR-Ig treatment in
other preclinical AIP models and compared its efficacy over other
treatment approaches such as the depletion of B cells using aCD20
treatment. As cellular immune responses also contribute to the
pathologyofAIP,we includedanarmof anti-CD4 (aCD4) treatment,
leadingto thedepletionofCD4+TcellsandregulatoryTcells (Tregs).
MATERIALS AND METHODS
Animal husbandry and samples
Animalsweremaintainedunder specificpathogen-freeconditions,
and experiments were approved and conform to the guidelines of
the Swiss Animal Protection Law, Veterinary Office (Zurich,
Switzerland). MRL/Mp mice were purchased from The Jackson
Laboratory. Both male and female Tg(Ela1-LTab) mice were used
for thedescribedexperiments; however inMRL/Mpand IL-102/2
animals, AIP is only inducible in female animals (12, 13).
RNA extraction
RNA was extracted and used for real-time PCR as described
previously (14, 15) or with a newly established method using the
Precellys 24 dual homogenizer with MagNA Lyser Green Beads
fromRocheAppliedScience. In short, a small piece of snap-frozen
tissuewas transferred toa tubecontainingbeads, 650ml of lysis buffer
(QIAGEN) was immediately added, and the tube was immediately
transferred to the Precellys and homogenized once at 6000 rpm for
30 s.TheRNAwasextracted following theQIAGENRNeasyMiniKit
extractionprotocolwith anon-columnDNasedigestion step. Purified
RNA was reversely transcribed into cDNA using qScript cDNA
SuperMix von Quantabio, according to the manufacturer’s protocol.
Real-time PCR
For mRNA expression analysis, real-time PCR was performed
using specific TaqMan probes (Applied Biosystems). Real-time
PCRwas runona 7500FastReal-TimePCRSystemusingTaqMan
Fast Universal PCR Master Mix (Applied Biosystems) under
standard conditions. Transcript levels were quantified using 18S
RNA (Applied Biosystems) as a reference and normalized.
Histology and immunohistochemistry
Paraffin (3-mm) sections of pancreas were stained with H&E or
various primary and secondary Abs. Paraformaldehyde (4%) fixed
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and paraffin-embedded tissue was incubated in Ventana buffer,
and staining was performed on a NEXES immunohistochemistry
robot (VentanaMedical Systems) using an iVIEWDABDetection
Kit (Ventana Medical Systems) or on a BOND-MAX (Leica
Biosystems) system. Deparaffinization and antigene retrieval was
performed in a PTLink pretreatmentmodule with target retrieval
solutions and stained on an Autostainer Link 48 (Dako, Glostrup,
Denmark). Abs as summarized below.
The Abs used are as follows: B220 (clone RA3-6B; host: rat
[550286; BDPharmingen]; dilution 1:50); CD3 (host: rabbit [IR503;
Dako]; ready to use); F4/80 (clone BM8; host: rat [BMA T2006;
BMA Biomedicals]; dilution 1:100); Ki67 (clone SP6; host: rabbit
[Ab 16667; Abcam]; dilution 1:200); Rel A (host: rabbit [RB-1638-
P0; LabVision]; dilution 1:500); Rel B (host: rabbit [Sc-226; Santa
Cruz Biotechnology]; dilution: 1:400); pStat3 (host: rabbit; dilution
1:100); PNad (host: rat [sc19602; SantaCruzBiotechnology]; dilution
1:250); FDCM-1 (host: rat [51320; BD Pharmingen]; dilution 1:60);
CD21/35 (host: rabbit [55553817; BD Pharmingen]; dilution 1:2000);
CD4 (host: rat; dilution 1:50); and CD8 (host: rat; dilution 1:200).
Immunohistochemistry of kidneys was performed on paraffin-
embedded materials as previously described (16). In brief, the
sections were deparaffinized, rehydrated, and incubated in 3%
hydrogen peroxide to block endogenous peroxidases. Endogenous
biotin was blocked by the Avidin/Biotin Blocking Kit (Vector
Laboratories, Burlingame, CA). An autoclave oven (or microwave
treatment) was used for heat-based Ag retrieval. Incubation with
theprimaryAbwasperformed for 1horovernight. Incubationwith
biotinylated secondary Abs (Vector Laboratories)was followed by the
avidin–biotin complex reagent (Vector Laboratories). 3939-Diamino-
benzidine (Sigma, Taufkirchen, Germany) with metal enhancement
was used as a detection system. Consecutive sections were stained
for mouse IgG (Vector Laboratories). Glomerular staining was
quantified for IgG deposits in the mesangium and in peripheral
glomerular capillaries using semiquantitative scores (from 0 to 3).
Paraffin-embedded pancreas specimens were immunostained
for amylase and CK19. Acinar-to-ductal metaplasia (ADM) lesions
were manually counted in a blinded fashion across the entire
pancreas slide of individual mice. ADM was identified according
to 1) the loss of amylase content, 2) positivity for CK19, and 3)
structural reorganization into tubular complexes.
The primary Abs used for immunofluorescence staining were
rabbit anti–a-amylase, fractionated antiserum (1:2000, A8273;
Sigma), and rat anti-mouse cytokeratin 19 (1:25; DSHB; TROMA-
III, developed by R. Kemler, Max-Planck Institute of Immunobi-
ology and Epigenetics, Freiburg, Germany) followed by the
incubation with matched secondary Abs Alexa Fluor 594 goat
anti-rabbit IgG (1:200, A11012; Thermo Fisher Scientific) and
Alexa Fluor 488 goat anti-rat IgG, respectively (1:200, A1106;
Thermo Fisher Scientific). Nuclei were visualized byDAPI staining.
Sampleswereanalyzedbyresearchersandpathologist inablinded
fashion without previous knowledge of the experimental groups.
Treatment with polyinosinic:polycytidylic acid
Polyinosinic:polycytidylic acid (Poly IC) was purchased by Sigma
(P1530) and applied in 6-wk-old IL-102/2 mice or 8-wk-old
MRL/Mp (n = 6 per group) mice i.p. with 5 mg/kg Poly IC
(stock 1 mg/ml) three times aweek. The duration of AIP induction
in IL-102/2mice was 6 wk and in MRL/Mp mice 4 wk.
Treatment with LTbR-Ig
Twelve-mo-old Tg(Ela1-LTa,b) and twelve-wk-old IL-102/2 and
MRL/Mpmicewith establishedAIPwere injected i.p.with 100mg
LTbR-Ig fusionprotein orwithMOPC21 (control IgG) for 4wkon
a weekly basis. As MOPC21 treatment results did not differ
significantly from untreated mice, data are not separately shown.
After 4 wk of treatment, mice were sacrificed, pancreas was
resected, and serum was obtained through cardiac puncture.
LTbR-Ig fusion protein and with MOPC21 (control IgG) were
provided by Biogen (Cambridge, MA).
Treatment with aCD4 and aCD20 Abs
Twelve-mo-old Tg(Ela1-LTa,b) and twelve-wk-old IL-102/2 and
MRL/MpmicewithestablishedAIPwere injected i.p.with200mg
aCD20 or 200mg aCD4Abs for 4wk on aweekly basis. After 4wk
of treatment, mice were sacrificed, pancreas was resected, and
serum was obtained through cardiac puncture. aCD20 Ab (clone
18B12-mIgG1) was provided by Biogen.
Serum antilactoferrin Ab test
Microtiter plates (MaxiSorp; Nalge NUNC, Roskilde, Denmark)
were coated with 20mg/ml of lactoferrin (LF) (Sigma Chemicals)
in 100 ml of 50-mM sodium carbonate buffer (pH 9.5) and kept
overnight at 4°C. The coated wells were washed three times with
PBS and blockedwith 5% nonfat milk in PBS for 2 h at 37°C. After
threewashes with PBS, eachwell was incubatedwith 100ml each
of mouse serum sample diluted at 1:10 with PBS containing 2%
nonfat milk for 2 h at room temperature. The wells were then
washed with PBS and incubated with phosphatase-conjugated
goat anti-mouseAbs (BioSource) for 1hat roomtemperature.After
three washes with PBS, the bound Abs were detected with
phosphatase substrate (Dako). The plates were read at 405 nm
using an ELISA plate reader (Vmax; Molecular Devices, Tokyo,
Japan).
IgG ELISA
The mouse IgG1 was quantified by Ready-SET-Go! ELISA (88-
50410; eBioscience), according to themanufacturer’s instructions.
Serums from Tg(Ela1-LTa,b), IL-102/2, and MRL/MP mice with
AIP were used for the assay.
Flow cytometry
The freshly harvested pancreaswas cut into pieces and digested in
McCoy 5A Medium containing 10% FBS, 1 mg/ml collagenase D
(11088858001; Sigma-Aldrich), and DNase I (10104159001; Sigma-
Aldrich) on a shaker at 450 rpm for 25 min at 37°C. Cells were
filtered with a cell strainer (100 mM) followed by a centrifugation
for 5 min at 1500 rpm, and the pellet was washed in PBS. Samples
were incubated with Abs for at least 30 min in the dark at 4°C
before washing in PBS and fixed in FACS buffer (50% PBS and
50of4%PFA). Isolatedpancreatic immunecellswere stainedwith
https://doi.org/10.4049/immunohorizons.2000079

















































FIGURE 1. Treatment schedule and pancreatic histology.
(A) Schematic representation of AIP development and treatment schedule in Tg(Ela1-Lta,b) mice. (B) Immunohistochemical analysis of B cells
(B220), T cells (CD3), and macrophages (F4/80) in 12-mo-old Tg(Ela1-Lta,b) mice upon treatments (n = 10). Stainings are representative of at least
five independent experiments. (C) Pancreatic damage was assessed by a blinded observer after treatments (n = 6). Number of ADM quantified on
H&E staining and normalized to the total surface of pancreas in Tg(Ela1-Lta,b) mice. Quantification of acinar cell proliferation based on counting of
Ki67+ nuclei (n = 8). Scale bar, 100 mm. *p , 0.05, ***p , 0.001.
https://doi.org/10.4049/immunohorizons.2000079

















































CD45 (109826), CD8a (100711), CD4 (100453), CD19 (557399),
F4/80 (123113),CD11c (117309),PCDA-1 (127009),CD49b(103503),
CD45R/B220 (103221), and CD3e (100305). All Abs mentioned
above were purchased from BioLegend.
SampleswereacquiredusingBDFACSCanto II (BDBiosciences)
and analyzed with FlowJo v9.8.5 software (Tree Star).
Statistical analyses and software
GraphPad Prism version 5 (La Jolla, CA) was used to construct
figures and diagrams. The data are presented as themean6 SEM.
One-way ANOVAwith Dunnett correction or unpaired t tests and
Mann–Whitney tests were used where appropriate. Differences
were considered statistically significant if p , 0.05 and were
marked with an asterisk.
RESULTS
LTbR-Ig and aCD20 treatment improve AIP
Tg(Ela1-Lta,b) mice spontaneously develop AIP at 9–12mo of age.
The inflammatory reaction inmicewithAIPhasbeencharacterized
by immunohistochemistry andflowcytometry (Fig. 1B, Supplemental
Fig. 1D). The analysis showed a high accumulation of T and B cells
as well as macrophages and a mild infiltration of plasmacytoid
dendritic cells (pDCs) inmicewithAIP. To compare the treatment
efficacy of LTbR-Igwith depletion of B andCD4T cells,micewith
established AIP were injected with the respective treatment
regimens starting 12mo of age (Fig. 1A). During the treatments, the
percentage of peripheral T and B cells were monitored in all three
treatment groups (Supplemental Fig. 1A). As expected, injection
with aCD20 Ab reduced peripheral B cells. Similarly, upon aCD4
Ab injection, a gradual decrease of CD4+ T cells was observed.
However, in the LTbR-Ig treatment group, CD4+ T cell and B cell
levels did not change.
We next assessed pancreatic pathology with a focus on the
presence of inflammatory cells following treatments in the three
treatment groups (Fig. 1B). As reported before (5), 12-mo-old
untreated Tg(Ela1-Lta,b) mice harbor large follicles constituting
of T and B cells and an extensive number of infiltrating
macrophages. LTbR-Ig treatment resulted in a significant de-
crease in B and T cell as well as macrophage infiltration. Periodic
injection of aCD20 improved overall pancreatic pathology, mostly
shown by more intact lobes and less infiltrating F4/80+
macrophages. Upon CD4+ T cell depletion, numerous lymphoid
follicles, predominatelyfilledwithBcellswithdiffusely infiltrating
T cells, remained in the pancreatic lobes.Macrophage influx in the
aCD4 treatment group was higher than aCD20 treatment group.
Blinded analysis of H&E staining showed the most prominent
improvement in pancreatic histology in the LTbR-Ig treatment
group and significant amelioration in the aCD20 group (Fig. 1C).
Blocking LTbR signaling prevented pancreatic injury
In response to injury, the pancreas activates regenerative process-
es to maintain tissue homeostasis. The prevailing concept is that
after injury, 1) exocrine pancreatic cells (acinar, centroacinar, and
ductal cells) start to proliferate or 2) acinar cells dedifferentiate
into ductal or progenitor cells as part of a self-defense mechanism
or regeneration (17) (ADM). Therefore, we assessed the pro-
liferationof acinar and inflammatory cells in the pancreas after the
treatment regimens. Our results indicate that compared with the
T and B cell depletion treatment, LTbR-Ig significantly reduced
acinar cell proliferation (Fig. 1C); however, none of the treatments
affected theproliferationof infiltratingcells (SupplementalFig. 1B).
As a regenerative response, we quantified acinar transdifferentia-
tion by counting ADM. Only LTbR-Ig treatment significantly
reduced ADM formation, ductal complexes, and acinar pro-
liferation (Fig. 1C), as shown by the assessment of morphology
on H&E (Supplemental Fig. 1C), transdifferentiation by amylase
andCK19 staining, and Sox9 gene expression (Supplemental Fig.
1E, 1F). The other two treatments did not influence the acinar
transdifferentiation. These results suggest that inhibiting LTbR
signaling reduces injury signals, leading to diminished injury and
hence less need for a regenerative response.
Inhibition of LTbR signaling moderates local
inflammatory reaction
Acinar cell injury also leads to local inflammatory reaction. There
is evidence showing that acinar cells can produce inflammatory
mediators such as chemokines and cytokines (18). Additionally,
infiltrating immune cells also contribute to the inflammatory
signature. For that reason, after the three treatment regimens, we
analyzed the above-mentioned factors (Fig. 2). LTbR-Ig and
aCD20 treatment significantly reduced the inflammatory cytokine
(IL-6, IL-1b, and Mip3b) and chemokine response (Mcp1), genes
involved in lymphocyte activation and attraction (Baff,Cxcl13, and
Ccl20), and further members of the TNF superfamily (Tnfa and
Light). However, depletion of CD4+T cells could only significantly
affect Ccl20 and Cxcl13 gene expression. The adhesion molecule
(Vcam) and expression of LT (Lta and Ltb) were not significantly
affected by any treatment (Fig. 2).
We further evaluated the Th cell subsets on the mRNA level,
based on their distinct cytokine expression profile and prototypic
transcription factors (TF). During AIP, predominantly Th1 and
Th2 type cells are present (5) in untreated mice (Fig. 3A). aCD20
treatment did not significantly influence the Th cell subsets,
whereas aCD4 Ab significantly decreased Th1 and mainly Th2
response. On the contrary, LTbR-Ig treatment resulted in a
significant reduction of T-bet and Th1 cytokines (Fig. 3A). No
difference in the expression of Th17 cytokines was observed,
supporting the hypothesis that Th17 cells are not involved in type 1
AIP pathogenesis (19). Although the TF Rorgt is upregulated in
Tg(Ela1-Lta,b) mice, this TF is also expressed by lymphoid tissue
inducer cells and lymphoid tissue inducer–like cells (20). Tregs
have also been shown to be elevated during AIP in humans and
mice (5, 21, 22). All treatmentswere able to decrease thenumber of
infiltrating Tregs (Fig. 3A). Treg-specific cytokines (IL-10 and
TGF-b) displayed a trend of lower expression in the LTbR-Ig and
aCD20 treatment groups.
As rodents have no subclass of IgG4,we assessed IgG1 levels as
it is suggested to serve as its counterpart in mice. We observed a
https://doi.org/10.4049/immunohorizons.2000079

















































reduction in IgG1 as a result of LTbR-Ig treatment but not upon
aCD20 (Supplemental Fig. 4D).
To define the cellular and molecular mechanisms of the
treatment response, we analyzed the activation of two key TFs
involved in pathological processes in the pancreas, including AIP
(5): NF-kb and Stat3 (23, 24) (Fig. 3B, Supplemental Fig. 2). In
untreated Tg(Ela1-Lta,b) mice, prominent Stat3 phosphorylation
was detected on acinar and inflammatory cells. Quantification of
Stat3-positive nuclei showed that aCD20 and LTbR-Ig treatments
significantly reduced Stat3 activation in acinar cells but not in
inflammatorycells (Fig. 3B, Supplemental Fig2B). aCD4 treatment
did not show any beneficial effect on Stat3 activation. We further
identified pronounced nuclear translocation of RelB in the acinar
cells and inflammatory cells, in contrast to RelA, which remained
mainly cytoplasmic (Supplemental Fig. 2A). Conversely, the activa-
tion of the noncanonical NF-kb signaling was only influenced by
LTbR-Ig treatment as blockingLTbRsignaling significantly reduced
RelB nuclear translocation on acinar and inflammatory cells. The
results of the detailed molecular characterization of the treatments
are summarized in Table I.
LTbR-Ig could sufficiently disrupt tertiary lymphoid organs
Tertiary lymphoid organs (TLOs) are important inductive sites for
self-reactive T lymphocytes and Abs that contribute to pathology
in autoimmune diseases. Only LTbR-Ig treatment could success-
fully disrupt characteristic structures of TLOs, like high endothe-
lial venules (PNad), follicular dendritic cell networks (FDCM1),
and germinal center B cells (CD21/35) (Fig. 4A). In addition, the
proportion of CD4+ and CD8+ T cells in the follicles was reduced.
We noticed significantly lower autoantibodies directed against LF
in LTbR-Ig– and aCD20–treated groups (Fig. 4B).
IgG4-related disease is a systemic disease including involve-
ment of other organs (e.g., salivary gland, bile ducts, or manifesta-
tions in the kidney) (5). Therefore, the incidence of IgG deposits
in the mesangium and capillaries in the kidneys upon different
treatment modalities were analyzed by light microscopy. Our
results indicate that all three treatments could sufficiently
reduce the extrapancreaticmanifestation in the kidney (Fig. 4C).
Assessments of bile ducts and salivary glands showed no morpho-
logical alterations in untreated (Tg(Ela1-LTa,b)mice (Supplemental
Fig. 2D and data not shown).
FIGURE 2. Expression analysis of genes involved in AIP.
Quantitative RT-PCR analysis of pancreatic tissue in Tg(Ela1-Lta,b)–treated mice (n = 5) and in wild type littermates (n = 4). Experiments were
performed in duplicates. Data are representative of two independent experiments. *p , 0.05, **p , 0.01, ***p , 0.001.
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AIP development is associated with LTbR signaling in
IL-102/2 and MRL/Mp mouse models
To validate the effect of LTbR-Ig treatment and evaluate immune
cell depletion in AIP, we studied two additional experimental
mouse models of AIP. MRL/Mp (12) and IL-102/2mice (13) have
been shown to develop type 1 AIP after repetitive injection with
Poly IC. The induction and progression of AIP as well as the
treatment allocation is depicted inFig. 5Aand5B.Given thatLTbR
signaling plays an important role in AIP development in mice and
humans (5),wefirst investigated the expressionofLTbR ligands in
AIP of MRL/Mp and IL-102/2 mice (Fig. 5C). The ligands Lta,
Ltb, and Light were significantly upregulated in both models,
supporting that LTbR signaling contributes to the development
of AIP. Furthermore, an activation of the noncanonical NF-kb
signaling was observed in the pancreas of MRL/Mp mice
(Supplemental Fig. 2C) upon Poly IC injection, similar to the
Tg(ELa1-Lta,b)mice. Thisfinding further verifies the involvement
of LT a and b and the noncanonical NF-kb signaling in AIP and
makes the MRL/Mp and IL-102/2models applicable to study the
effects of LTbR-Ig and immune cell depletion.
FIGURE 3. Cellular and molecular mechanisms of treatment response.
(A) Quantitative RT-PCR analysis of pancreatic Tnf-a, Ifn-g, T-bet, Gata3, Il4, Il5, Rorgt, Il17, Tgfb, and Il10 transcripts in untreated 12-mo-old
Tg(Ela1-LTab) mice and mice treated with aCD20, aCD4, and LTbR-Ig (n = 5). Experiments were performed in duplicates. Data are representative of
two independent experiments. (B) Quantification of Stat3+ acinar cells and RelB nuclear translocation in acinar cells and in infiltrating immune cells
of 12-mo-old Tg(Ela1-LTab) (n = 4 untreated, n = 5 treated mice) and C57BL/6 controls (n = 3). *p , 0.05, **p , 0.01, ***p , 0.001.
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Validating the therapeutic efficacy of LTbR-Ig and aCD20
in LT-independent mouse models
In MRL/Mp and IL-102/2 mice, the treatments started when
mice already had established autoimmunity. Mice were
subjected to weekly i.p. injections of the respective therapy
for 4 wk and harvested consecutively (Fig. 5B). Treatment
efficacywas assessed by 1) histological evaluation of infiltrating
inflammatory cells and TLOs (Fig. 6), 2) cytokine and chemokine
expression (Supplemental Figs. 3A, 4A), and 3) quantification of
autoantibodies against pancreatic Ags (LF) (Supplemental Figs.
3B, 4B).
In theMRL/Mpmodel, severe histopathological changeswere
observed after Poly IC administration, replacing almost all pancreatic
lobes (marked inflammatory cell infiltration with complete destruc-
tion of acini and pancreatic parenchyma, ductal complexes, and
strong fibrosis) (Fig. 6A). LTbR-Ig and aCD20 treatment did not
result in a significant benefit in the MRL/Mp model, based on the
histological evaluation.However, aCD20 injection showed a trend of
reduced inflammatory gene expression (Fig. 6C, Supplemental Fig.
3A) and reduced autoantibody level (Supplemental Fig. 3B) but no
changes in Igs (Supplemental Fig. 4D). In agreement with the
previousexperiment inTg(Ela1-Lta,b)mice,LTbR-Igbutnot aCD20
could significantly reduce the number of TLOs in the pancreatic
parenchyma of MRL/Mp mice; however, numerous TLOs still
remained in the tissue (Fig. 6C).
In IL-102/2 mice, administration of Poly IC induced a more
consistent, specific destruction of the exocrine pancreatic tissue
but milder than observed in the MRL/Mp mice (Fig. 6B). Upon
both LTbR-Ig and aCD20 treatment, IL-102/2 AIP model had
significantly reduced diffuse inflammatory infiltration, ADM, and
edema almost similar to Tg(Ela1-Lta,b) mice. Furthermore, pancre-
atic cytokine (Il6 and Il1b) and chemokine (Mcp1) expression and
genes involved in lymphocyte activation and attraction (Baff,Cxcl13,
and Ccl20) were also decreased (Supplemental Fig. 4A). Measure-
ment of pancreatic autoantibodies and IgG1 also revealed a
strong trend of reduction with both treatments (Supplemental Fig.
4B,4D).Next,weassessedacinarcell proliferationbasedonKi67+by
immunohistochemistry.Our results indicate, similarly toTg(Ela1-Lta,b)
mice, that only LTbR-Ig treatmentwas able to significantly reduce
acinar cell proliferation in mice with AIP (Supplemental Fig. 4C).
TABLE I. Summary of molecular characterization of the treatment groups
https://doi.org/10.4049/immunohorizons.2000079

















































We thereby confirmed the efficacy of LTbR-Ig and aCD20
treatments to alleviate AIP induced in IL-102/2mice.
DISCUSSION
AIP is a recently discovered disease of the pancreas, with
suspected autoimmune causes. To understand AIP, we previously
developedanovel transgenicmousemodelmimickinghumanAIP.
The model is based on the overexpression of LT in the pancreas,
which results in the development of type I AIP, with a robust
penetrance and phenotypic reproducibility. In this study, we used
this novel genetic model of AIP to analyze the detailed molecular
mechanisms of LTbR-Ig treatment to alleviate AIP. The strength
of the study is that we validated the efficacy of LTbR-Ig treatment
FIGURE 4. Characterization of autoimmunity.
(A) Characterization of TLOs by visualizing PNad+ high endothelial venules, FDCM-1+ follicular dendritic cell networks, CD21/35+ germinal center B cells, CD4+
T cells, and CD8+ cytotoxic T cells in a follicle in 12-mo-old mice (scale bar, 50 mm). Stainings are representative of at least three independent experiments. (B)
Autoantibodies against LF were measured from the serum of transgenic mice by ELISA (n = 6 wild type; n = 20 untreated, and n = 8 treated groups).
Experiments were performed in duplicates and repeated three times. (C) Assessment of extrapancreatic manifestations in the kidneys of 12-mo-old Tg(Ela1-
LTab) mice (n = minimum 7). The stainings for the experiment represent two independent experiments. *p , 0.05, **p , 0.01, ***p , 0.001.
https://doi.org/10.4049/immunohorizons.2000079

















































FIGURE 5. Treatment schedule and characterization of MRL/Mp and IL-102/2 models of AIP.
(A) Table showing the experimental setup, summarizing which treatment was performed in which mouse model. (B) Treatment schedule for treating
AIP in MRL/Mp and IL-102/2 mice. Numbers in boxes represent experimental days. (C) Quantitative RT-PCR analysis of Lta, Ltb, Light, and LtbR
genes. Transcripts were analyzed in mRNA from pancreatic homogenates of MRL/Mp and IL-102/2 mice with established AIP (n = 7). Experiments
were performed in duplicates. Data are representative of two independent experiments. *p , 0.05, **p , 0.01.
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in another animal model of AIP (IL-102/2 induced with Poly IC),
which develops AIP without transgenic overexpression of LT.
Besides investigating the effectormechanisms of LTbR-Ig,we also
tested therapeutic strategies that seems to be beneficial for AIP
patients (i.e., depletion of CD20+ B cells and CD4+ T cells).
The principle finding of the study is that LTbR-Ig and aCD20
treatment were efficient to alleviate AIP in two animal models
of AIP [Tg(Ela1-Lta,b) and IL-102/2]. Both treatments led to a
significant decrease in autoantibody production and inflammatory
cell infiltration in the pancreas. The molecular mechanisms of this
beneficial effect possibly involve the downregulation of Stat3 and
noncanonical NF-kb activation. Importantly, LTbR-Ig proved to be
moreefficient in reducing theTLOburden,whichmakes it avaluable
candidate for the treatment of AIP. aCD4 treatment resulted in
reducedTh1andTh2polarization;however, thisdidnotalleviateAIP.
LTbR-Ig not only more efficiently reduced TLOs, but in
contrast to aCD20 and aCD4 treatments, it could significantly
decrease the proliferation rate of acinar cells and reduce the
number of ADMs. A higher proliferation rate in the aCD20 group
can also imply an increased regenerative process. However, in the
LTbR-Ig–treated group, the lower proliferation is proportional to
less ADM, which indicates that regeneration already took place as
ADMs are reversible. Our findings of the phenotypic character-
ization of Tg(Ela1-Lta,b) mice upon the different treatment
regimens are summarized in Table I. This table clearly shows
that LTbR-Ig treatment is associated with the most beneficial
effects on AIP pathogenesis (Table I).
These findings highlight an important point concerning the
immunopathogenesis of AIP. In recent years, two main theories
were proposed. The first concept involves an abnormal adaptive
immune response, leading to an increased accumulation of mostly
Th2 cells. Their cytokine production (e.g., IL-4, IL-10, and IL-13)
can promote IgG production by B cells, contributing to the
pathogenesis of AIP (25).
According to the second theory, T cells are secondary, and
innate immunity plays a fundamental role in AIP development.
Initial evidence for that was provided from studies showing that
B cells can induce IgG4 production by APCs (26, 27). Monocytes,
FIGURE 6. Histological assessment of treatments in MRL/Mp and IL-102/2 models of AIP.
(A) Pancreatic morphology visualized on H&E staining in one untreated MRL/Mp mice, two mice with AIP (treated with Poly IC), and three mice with
AIP and treated with LTbR-Ig or aCD20. Scale bar, 100 mm. (B) Pancreatic morphology visualized on H&E staining in an untreated IL-102/2 mice,
two mice with AIP (treated with Poly IC), and three mice with AIP and treated with LTbR-Ig or aCD20. Scale bar, 100 mm. (C) Histological assessment
of a blinded observer in the MRL/Mp and IL-102/2 model of AIP. Mice treated with Poly IC only (control n = 8) were compared with mice treated
with LTbR-Ig (n = 5) or aCD20 (n = 5). Stainings are representative of two to three independent experiments. *p , 0.05, **p , 0.01.
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basophils, and importantly, pDCs secreting IFN-a and BAFF can
induce IgG secretion by B cells in a T cell–independent manner.
Further evidence has been provided that pDCs are not only
associated with the development of murine AIP (MRL/Mp) but
also chronic fibroinflammatory responses are mediated by
activated pDCs producing IFNa and IL-33 (26).
Our results support the second concept as aCD4 treatment
significantly reduced Th2 cytokines but did not achieve any
benefits in terms ofAIP pathology. Furthermore, in Tg(Ela1-Lta,b)
mice, we detected slightly increasednumbers of pDCs, and LTbR-
Ig and aCD20 treatments significantly reduced BAFF expression.
Our results do not identify the cellular source of BAFF. Because
pDCs produce high levels of IFN-a in response to a stimulus, it is
possible to observe suddenIFN-a inMRL/Mpafter stimulus (Poly
IC). However, in the genetic Tg(Ela1-Lta,b) model, lack of an
external acute stimulus targeting pDC or other cells explains
undetectable IFN-a levels in the serum.
Interestingly, we measured high LT expression in MRL/Mp
model, but the administration of LTbR-Ig did not improve AIP in
terms of pancreatic morphology and inflammatory gene expres-
sion.ThemethodofAIP initiation is stimulationofTLR3 througha
synthetic dsRNA (Poly IC), which is conceptually different from
the induction of the LTbR and TNF pathways through pancreatic
LT overexpression. We would nonetheless like to point out that
LTbR-Ig treatment led to reduced tertiary lymphoid tissues in the
MRL/Mp model, which is an important pathological feature of
AIP. However, AIP induced by Poly IC in the IL-102/2 mice
responded well to LTbR-Ig treatment, ruling out an induction-
specific cause. Itmaybenoted thatMRL/Mpmice,whicharenot on
C57BL/6 background, develop a systemic autoimmunity that may
hinder a response to LTb-Ig treatment, whereas the genetic
background of IL-102/2 mice is C57BL/6, identical to Tg(Ela1-
Lta,b) mice. MRL/Mp mice exhibit massive destruction of
pancreatic architecture, and a potential regeneration could not be
supported by blocking LTbR signaling or depleting B cells (aCD20).
Therefore, further clinical studies with LTbR-Ig in human AIP should
focus on early/newly diagnosed disease or used as a second-line
treatment after the amelioration of inflammation by steroid
treatment. Plausibly, genetic predisposition of human AIP patients
(28, 29) might influence the treatment success, which should be
investigated in upcoming clinical studies.
In conclusion, in this comparative study, we provide mecha-
nistic support for two treatments that can be used to treat AIP
patients. We suggest introducing new therapeutic interventions
(i.e., LTbR-Ig and a treatment with rituximab [aCD20] that was
already tried on a small cohort of AIP patients).
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et al. 2014. Autoimmune pancreatitis in MRL/Mp mice is a T cell-
mediated disease responsive to cyclosporine A and rapamycin treatment.
Gut 63: 494–505.
9. Rueda, J. C., C. Duarte-Rey, and N. Casas. 2009. Successful treatment
of relapsing autoimmune pancreatitis in primary Sjögren’s syndrome
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